MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline in Securities Class Action
Plaintiff firms underscore allegations that SLK’s touted Nanobody advantages were undermined by Phase 3 results.
Overview
- Rosen Law Firm, Hagens Berman, the Law Offices of Howard G. Smith, and Faruqi & Faruqi are urging MoonLake shareholders to seek lead-plaintiff status by December 15, 2025.
- The putative class period runs from March 10, 2024 through September 29, 2025, and the cases are pending in the Southern District of New York.
- Complaints claim SLK and rival BIMZELX target the same cytokines IL-17A and IL-17F and that SLK’s Nanobody design did not deliver superior clinical benefit.
- Filings also allege that promised tissue penetration advantages for SLK did not translate into clinical efficacy in the VELA program.
- MoonLake disclosed week-16 VELA results on September 28, 2025, and the stock fell roughly 90% to close at $6.24 the next trading day; no class has been certified to date.